Chevy Chase Trust Holdings LLC Sells 14,835 Shares of Danaher Co. (NYSE:DHR)

Chevy Chase Trust Holdings LLC decreased its position in Danaher Co. (NYSE:DHR) by 3.6% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 402,187 shares of the conglomerate’s stock after selling 14,835 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Danaher were worth $111,816,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of DHR. FMR LLC boosted its stake in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. TD Asset Management Inc raised its holdings in Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after acquiring an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Danaher by 22.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after purchasing an additional 563,546 shares during the last quarter. International Assets Investment Management LLC grew its stake in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. increased its position in shares of Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

DHR opened at $239.00 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a 52-week low of $215.68 and a 52-week high of $281.70. The firm has a market cap of $172.62 billion, a P/E ratio of 45.74, a price-to-earnings-growth ratio of 4.41 and a beta of 0.85. The business’s fifty day moving average is $254.59 and its 200-day moving average is $259.41.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.02 earnings per share. Sell-side analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Ratings Changes

A number of brokerages recently weighed in on DHR. Evercore ISI boosted their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Wednesday, November 27th. TD Cowen raised their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, Robert W. Baird cut their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.